

DEC 1 2 2006

Food and Drug Administration Rockville MD 20857

Re: X-Stop Interspinous Process Decompression System
Docket No. 2006E-0259

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Patent Extension
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 6,235,030 filed by St. Francis Medical Technologies, Inc., under 35 U.S.C. § 156. The medical device claimed by the patent is X-Stop Interspinous Process Decompression System, which was assigned premarket approval application (PMA) No. P040001.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in *Glaxo Operations UK Ltd. v. Quigg*, 706 F. Supp. 1224 (E.D. Va. 1989), *aff'd*, 894 F. 2d 392 (Fed. Cir. 1990).

The PMA was approved on November 21, 2005, which makes the submission of the patent term extension application on January 19, 2006, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad

Associate Director for Policy

are a. afelia

Center for Drug Evaluation and Research

cc: Sheldon R. Meyer Fliesler Meyer LLP Customer # 23910

Four Embarcadero Center, 4th Floor

San Francisco, CA 94111-4156